1040246-87-4

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dichloro-3-pyridazinecarboxylic acid is used as an intermediate in the preparation of N-Heteroarylsulfonamide derivatives. These derivatives are being studied for their potential in treating hyperproliferative diseases, which are conditions characterized by the abnormal and rapid growth of cells. The compound plays a crucial role in the synthesis of these therapeutic agents, contributing to the development of novel treatments for such diseases.

Upstream product

• 372118-01-9 4,6-dichloro-pyridazine-3-carboxylic acid methyl ester 

Downstream Products

• 1040246-88-5 4-(4-bromo-2-fluorophenylamino)-6-chloropyridazine-3-carboxylic acid 

Relevant academic research and scientific papers

SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The nitrogen-containing heterocyclic compound or the pharmaceutically acceptable salt thereof of the present invention is useful as a prophylactic and/or therapeutic agent for, for example, skin diseases and the like. The present invention provides a heterocyclic compound represented by the following formula (I) {wherein, XA represents CH and the like, R1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, YA represents -NH- and the like, R2 represents a hydrogen atom and the like, R3A represents the following formula (R3A-1) (wherein, R3 represents hydroxy and the like) and the like, and R4A represents the following formula (R4A-1) (wherein, R4 and R5 are the same or different and each represents a hydrogen atom and the like) and the like}, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.

INHIBITORS OF MEK

This invention concerns to N-(2-aylamino) aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.